Movmedix has received its first U.S. FDA 510(k) clearance, enabling the commercial launch of its LARS ACJ system in the United States.
The French orthopaedic medtech company is bringing its LARS synthetic ligament platform to the U.S. market, beginning with the acromioclavicular joint indication. The LARS ACJ implant is a knitted surgical scaffold made from biocompatible polyethylene terephthalate and is intended to provide fixation during healing following syndesmotic trauma, including acromioclavicular separations due to coracoclavicular ligament disruption. These injuries can require long rehabilitation periods and may increase long-term risk of osteoarthritis, affecting both quality of life and healthcare costs.
The company cited more than 200,000 ACL injuries annually in the United States, while acromioclavicular joint dislocations represent around 10 per cent of all shoulder injuries in an urban population. Among athletes in contact sports, shoulder injury burden can be substantial.
The LARS platform has a long clinical history outside the United States. Movmedix said LARS technologies support more than 11 clinical indications, have been implanted in more than 250,000 patients worldwide and are supported by more than 100 peer-reviewed scientific publications.
The newly cleared LARS ACJ system includes the LARS ACJ implant, LARS screws and dedicated surgical instruments. Although this first clearance focuses on the shoulder, Movmedix is positioning the approval as the first step in a broader U.S. regulatory roadmap for its synthetic ligament portfolio.
The platform’s differentiation lies in synthetic ligament reinforcement and reconstruction, where biomaterial design, handling, fixation and long-term tissue response are important. Movmedix’s free-fiber technology has been used across multiple orthopaedic applications, particularly in knee ligament reconstruction.
Movmedix is preparing a phased U.S. commercial strategy, including establishing a local presence and developing strategic partnerships. The company is also engaging orthopaedic surgeons and sports medicine specialists to support clinical education and market development.
